LEO Pharma showcases promising results from DELTA 3 trial at AAD Congress
In a significant development within the field of medical dermatology, LEO Pharma A/S, a global leader renowned for its commitment to advancing dermatological care, presented ... Read More
EMA validates LEO Pharma’s application for delgocitinib cream in chronic hand eczema
LEO Pharma A/S said that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for delgocitinib cream. Touted as a groundbreaking topical ... Read More
Glenmark Pharmaceuticals gets FDA approval for generic Protopic Ointment
Glenmark Pharmaceuticals Ltd., a global leader in pharmaceutical research, has secured the final nod from the U.S. Food & Drug Administration (U.S. FDA) for its ... Read More
Glenmark gets FDA nod for generic of psoriasis medication Enstilar Foam
Glenmark Pharmaceuticals has secured tentative approval from the US Food and Drug Administration (FDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%. The product is the ... Read More
LEO Pharma secures global rights to JW1601 in $402m deal with JW Pharmaceutical
LEO Pharma, a leading Danish pharmaceutical company, has acquired global exclusive rights to the atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP), in a significant ... Read More